Management of advanced prostate cancer after first-line chemotherapy

Journal of Clinical Oncology

Volumn 23, Issue 32, 2005, Pages 8247-8252

  Berthold, Dominik R ^a   Sternberg, Cora N ^a   Tannock, Ian F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIINFECTIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CISPLATIN; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIETHYLSTILBESTROL; DOCETAXEL; ESTRAMUSTINE; ESTROGEN DERIVATIVE; ETOPOSIDE; FLUTAMIDE; GLUCOCORTICOID; HYDROCORTISONE; IXABEPILONE; KETOCONAZOLE; METHYLPHENIDATE; MITOXANTRONE; NARCOTIC AGENT; NAVELBINE; PREDNISONE; RADIOISOTOPE; SAMARIUM; SATRAPLATIN; STRONTIUM 89; TAXANE DERIVATIVE; VINCRISTINE; ANTINEOPLASTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADVANCED CANCER; BLOOD TOXICITY; BONE METASTASIS; BONE PAIN; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DISEASE CONTROL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG WITHDRAWAL; FRACTURE; HORMONE SENSITIVITY; HUMAN; MORBIDITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OSTEOSCLEROSIS; PALLIATIVE THERAPY; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SPINAL CORD COMPRESSION; THROMBOCYTOPENIA; THROMBOSIS; TOXICITY; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; CLASSIFICATION; DISEASE MANAGEMENT; MALE; PROSTATE TUMOR;

ANTINEOPLASTIC AGENTS; DISEASE MANAGEMENT; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS;

EID: 33644698567     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.1435     Document Type: Review

References (52)

1. Tannock IF, Osoba D, Stockler MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-1764, 1996
2. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004
3. Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520, 2004
4. Wilwerding MB, Loprinzi CL, Mailliard JA, et al: A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. Support Care Cancer 3:135-138, 1995
5. Bruera E, Driver L, Barnes EA, et al: Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: A preliminary report. J Clin Oncol 21: 4439-4443, 2003
6. Saad F, Gleason DM, Murray R, et al: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468, 2002
7. Ernst DS, Tannock IF, Winquist EW, et al: Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisoneand placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 21:3335-3342, 2003
8. Moore MJ, Osoba D, Murphy K, et al: Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 12:689-694, 1994
9. Stockler MR, Osoba D, Corey P, et al: Convergent discriminitive, and predictive validity of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) assessment and comparison with analogous scales from the EORTC QLQ-C30 and a trial-specific module: European Organisation for Research and Treatment of Cancer-Core Quality of Life Questionnaire. J Clin Epidemiol 52:653-666, 1999
10. Michels JE, Montemurro T, Kollmannsberger C, et al: First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer (HRPC): Does sequence matter? Proc Am Soc Clin Oncol 23:16s, 2005 (abstr 4611)
11. Saad F, Ruether D, Ernst S, et al: Canadian Urologic Oncology Group (CUOG) phase II multicenter study using docetaxel/prednisone in the second line setting for metastatic hormone-refractory prostate cancer in patients progressing after first line mitoxantrone/prednisone. Proc Am Soc Clin Oncol, 23:16s, 2005 (abstr 4612)
12. Oh WK, Manola J, Babcic V, et al: Response to second-line chemotherapy in patients with hormone refractory prostate cancer (HRPC) receiving two sequences of mitoxantrone (M) and taxanes (T). Proc Am Soc Clin Oncol, 23;16s, 2005 (abstr 4616)
13. Joshua AM, Nordman R, Venkataswaran M, et al: Weekly docetaxel as second line treatment after mitoxantrone for androgen-independent prostate cancer (AIPC). Proc Am Soc Clin Oncol, 23:16s, 2005 (abstr 4713)
14. Daliani DD, Assikis V, Tu SM, et al: Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Cancer 97:561-567, 2003
15. Glode LM, Barqawi A, Crighton F, et al: Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 98:1643-1648, 2003
16. Abratt RP, Brune D, Dimopoulos MA, et al: Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann Oncol 15:1613-1621, 2004
17. Kelland LR: An update on satraplatin: The first orally available platinum anticancer drug. Expert Opin Investig Drugs 9:1373-1382, 2000
18. McKeage MJ, Raynaud F, Ward J, et al: Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 15:2691-2700, 1997
19. Beale P, Raynaud F, Hanwell J, et al: Phase I study of oral JM216 given twice daily. Cancer Chemother Pharmacol 42:142-148, 1998
20. Kurata T, Tamura T, Sasaki Y, et al: Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexyl-amine-platinum (IV) (JM216) administered once a day for five consecutive days: A phase I study. Jpn J Clin Oncol 30:377-384, 2000
21. Sessa C, Minoia C, Ronchi A, et al: Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days. Ann Oncol 9:1315-1322, 1998
22. Latif T, Wood L, Connel C, et al: Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC). Invest New Drugs 23:79-84, 2005
23. Sternberg CN, Whelan P, Hetherington J, et al: Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 68:2-9, 2005
24. Bollag DM, McQueney PA, Zhu J, et al: Epothilones, a new class of microtubule stabilizing agents with a taxol-like mechanism of action. Cancer Res 55:2325-2333, 1995
25. Lee FY, Borzilleri R, Fairchild CR, et al: BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7:1429-1437, 2001
26. Goodin S, Kane MP, Rupin EH: Epothilones: Mechanism of action and biologic activity J Clin Oncol 22:2015-2025, 2004
27. Hussain M, Faulkner J, Vaishampayan U, et al: A phase II trial of epothilone-B analogue BMS-247550 (NSC #710428) administered every 21 days in patients with hormone refractory prostate cancer: Southwest Oncology Group Study S011. Proc Am Soc Clin Oncol 22:384s, 2004 (abstr 4510)
28. Galsky MD, Small EJ, Oh WK, et al: Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 23:1439-1446, 2005
29. Rosenberg JE, Kelly WK, Michaelson MD, et al: A randomized phase II study of ixabepilone (Ix) or mitoxantrone and prednisone (MP) in patients with taxan (T)-resistant hormone refractory prostate caner (HRPC), Proc Am Soc Clin Oncol, 23:16s, 2005 (abstr 4566)
30. Porter AT, McEwan AJ, Powe JE, et al: Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25:805-813, 1993
31. Quilty PM, Kirk D, Bolger JJ, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer Radiother Oncol 31:33-40, 1994
32. Oosterhof GO, Roberts JT, de Reijke TM et al: Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: A phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 44:519-526, 2003
33. Serafini AN, Houston SJ, Resche I, et al: Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial. J Clin Oncol 16:1574-1581, 1998
34. Sartor O, Reid RH, Hoskin PJ, et al: Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 63:940-945, 2004
35. Henriksen G, Fisher DR, Roeske JC, et al: Targeting of osseous sites with alpha-emitting 223Ra: Comparison with the beta-emitter 89Sr in mice. J Nucl Med 44:252-259, 2003
36. Nilsson S, Balteskard L, Fossa SD, et al: Phase I clinical trial exploring the bone-seeking alpha emitter radium-233 in patients with skeletal metastases from breast and prostate cancer. Proc Am Soc Clin Oncol 22:240, 2003 (abstr 963)
37. Tannock I, Gospodarowicz M, Meakin W, et al: Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590-597, 1989
38. Khandwala HM, Vassilopoulou-Sellin R, Logethetis CJ, et al: Corticosteroid-induced inhibition of adrenal androgen production in selected patients with prostate cancer. Endocr Pract 7:11-15, 2001
39. Fossa SD, Slee PH, Brausi M, et al: Flutamide versus prednisone in patients with prostate cancer symptomaticaliy progressing after androgen-ablative therapy: A phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 19:62-71, 2001
40. Small EJ, Halabi S, Dawson NA, et al: Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583). J Clin Oncol 22:1025-1033, 2004
41. Oh WK: The evolving role of estrogen therapy in prostate cancer. Clin Prostate Cancer 1:81-89, 2002
42. Small EJ, Frohlich MW, Bok R, et al: Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer J Clin Oncol 18:3595-3603, 2000
43. Oh WK, Kantoff PW, Weinberg V, et al: Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethyistilbestrol in patients with androgen independent prostate cancer. J Clin Oncol 22: 3705-3712, 2004
44. Lundgren R, Nordle O, Josefsson K: Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer a randomized multicenter study with 15 years of followup: The South Sweden Prostate Cancer Study Group. J Urol 153:1580-1580, 1995
45. Andersson L, Berlin T, Boman J, et al: Estramustine versus conventional estrogenic hormones in the initial treatment of highly or moderately differentiated prostatic carcinoma: A randomized study. Scand J Urol Nephrol Suppl 55:143-145, 1980
46. Taplin ME, Rajeshkumar B, Halabi S, et al: Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21:2673-2678, 2003
47. Marques RB, Erkens-Schulze S, de Ridder CM, et al: Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment. Int J Cancer, 2005
48. Balk SP: Androgen receptor as a target in androgen-independent prostate cancer. Urology 60:132-8: discussion 138-9, 2002
49. Rennie PS, Nelson CC: Epigenetic mechanisms for progression of prostate cancer Cancer Metastasis Rev 17:401-409, 1998
50. Isaacs JT: The biology of hormone refractory prostate cancer: Why does it develop? Urol Clin North Am 26:263-273, 1999
51. Miyamoto H, Rahman MM, Chang C: Molecular basis for the antiandrogen withdrawal syndrome. J Cell Biochem 91:3-12, 2004
52. Shamash J, Dancey G, Barlow C, et al: Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer Reinduction of endocrine sensitivity an unexpected finding. Br J Cancer 92:36-40, 2005